CFO Christopher R. Cline sold Travere Therapeutics ($TVTX) shares on the open market nine times over the past year, totaling about $1.05 million. His most recent sale occurred on February 4, 2026. These sales rank 4,811th among 11,678 insiders in our database, where the average is $8.6 million across roughly 6.4 transactions per insider. Cline made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Common Stock | 4250 | $0.00 | 121,149.0000 | 89,211,813 | 3.64% | 0.00% |
| May 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Performance-based restricted stock units | 4250 | $0.00 | 4,250.0000 | 89,211,813 | 50.00% | 0.00% |
| May 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Performance-based restricted stock units | 8500 | $0.00 | 8,500.0000 | 89,211,813 | 9999.99% | 0.01% |
| May 6, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 310 | $43.95 | 118,658.0000 | 89,211,813 | 0.26% | 0.00% |
| May 5, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 2181 | $46.65 | 118,968.0000 | 89,211,813 | 1.80% | 0.00% |
| April 13, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 65 | $28.85 | 125,161.0000 | 89,211,813 | 0.05% | 0.00% |
| April 15, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 1014 | $42.61 | 116,899.0000 | 89,211,813 | 0.86% | 0.00% |
| April 14, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 7239 | $41.93 | 117,913.0000 | 89,211,813 | 5.78% | 0.01% |
| April 14, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 9 | $41.07 | 125,152.0000 | 89,211,813 | 0.01% | 0.00% |
| April 13, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Common Stock | 14000 | $0.00 | 125,226.0000 | 89,211,813 | 12.59% | 0.02% |
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 110 | $32.90 | 111,226.0000 | 89,211,813 | 0.10% | 0.00% |
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 1635 | $32.14 | 111,336.0000 | 89,211,813 | 1.45% | 0.00% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 7242 | $32.12 | 112,971.0000 | 89,211,813 | 6.02% | 0.01% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Employee stock option (right to buy) | 75000 | $0.00 | 75,000.0000 | 89,211,813 | 9999.99% | 0.08% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Common Stock | 28130 | $0.00 | 120,213.0000 | 89,211,813 | 30.55% | 0.03% |
| Dec. 1, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Common Stock | 20000 | $16.23 | 112,083.0000 | 102,618,560 | 21.72% | 0.02% |
| Dec. 1, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Employee stock option (right to buy) | 20000 | $0.00 | 0.0000 | 102,618,560 | 100.00% | 0.02% |
| Dec. 1, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 20000 | $35.01 | 92,083.0000 | 102,618,560 | 17.84% | 0.02% |
| Sept. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 454 | $18.20 | 92,202.0000 | 78,888,861 | 0.49% | 0.00% |
| Sept. 4, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 119 | $19.71 | 92,083.0000 | 78,888,861 | 0.13% | 0.00% |
| Aug. 27, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 470 | $17.31 | 92,656.0000 | 78,888,861 | 0.50% | 0.00% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Common Stock | 4920 | $0.00 | 94,910.0000 | 78,888,861 | 5.47% | 0.01% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | M | Performance-based restricted stock units | 4920 | $0.00 | 4,920.0000 | 78,888,861 | 50.00% | 0.01% |
| May 5, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 1784 | $21.05 | 93,126.0000 | 78,888,861 | 1.88% | 0.00% |
| April 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 48 | $13.14 | 89,990.0000 | 78,888,861 | 0.05% | 0.00% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Common Stock | 21500 | $0.00 | 95,230.0000 | 78,888,861 | 29.16% | 0.03% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Employee stock option (right to buy) | 58000 | $0.00 | 58,000.0000 | 78,888,861 | 9999.99% | 0.07% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 5192 | $20.12 | 90,038.0000 | 78,888,861 | 5.45% | 0.01% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 865 | $18.94 | 73,730.0000 | 78,888,861 | 1.16% | 0.00% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 2490 | $11.52 | 74,595.0000 | 74,267,418 | 3.23% | 0.00% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Common Stock | 6750 | $0.00 | 77,085.0000 | 74,267,418 | 9.60% | 0.01% |
| Sept. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 514 | $9.51 | 70,335.0000 | 74,267,418 | 0.73% | 0.00% |
| April 11, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 54 | $6.74 | 70,849.0000 | 74,267,418 | 0.08% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Employee stock option (right to buy) | 65000 | $0.00 | 65,000.0000 | 74,267,418 | 9999.99% | 0.09% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | A | Common Stock | 25000 | $0.00 | 74,721.0000 | 74,267,418 | 50.28% | 0.03% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 3818 | $8.53 | 70,903.0000 | 74,267,418 | 5.11% | 0.01% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | Cline Christopher R. | CHIEF FINANCIAL OFFICER | S | Common Stock | 853 | $9.07 | 49,721.0000 | 74,267,418 | 1.69% | 0.00% |